Latest Headlines

Latest Headlines

Perrigo CEO calls on his Israeli investors to block Mylan bid

Perrigo has railed repeatedly against Mylan's hostile takeover bid and introduced massive cost-cuts and streamlining efforts to try to keep its shareholders loyal. Its next step in fending off its unwanted suitor? Heading to Israel.

Healthcare, wellness drive Philips growth as it works to shed lighting, maintain cautious M&A strategy

Royal Philips has hit a regulatory stumbling block with the $3.3 billion sale of 80% of its combined Lumileds and automotive lighting businesses, which it has already separated out as discontinued operations on its balance sheet. Philips also hasn't yet sorted out its strategic plans for its remaining Lighting business, which it said it will separate out during the first half of 2016.

Report: Buyer interest heating up for Swiss Dx company Unilabs

Amid a recent flurry of healthcare company consolidations, buyouts and sales this year, interest in snapping up Unilabs is heating up following last month's news that the Swiss diagnostics company was for sale.

Shire's not giving up on target Baxalta, it says amid Q3 beat

Shire's been quiet on the Baxalta front for a while now, but that doesn't mean its quest to buy the newly formed Illinois drugmaker is over.

Perrigo to slash 800 jobs, buy back $2B of its stock in move to fend off Mylan

Some industry watchers have predicted that Perrigo would make shareholder-friendly moves to persuade investors not to accept Mylan's hostile tender offer. And now--leading with job and cost cuts--the Dublin drugmaker is doing just that.

Teva mulls $7B stock offering to help fund Allergan generics buy

Teva's $40.5 billion deal for Allergan's generics company is going to help Allergan pay down much of its dealmaking debt. But in the meantime, the Israeli pharma needs some acquisition money of its own--and it's reportedly planning to raise as much as $7 billion this year to help fund the transaction.

Small cap NeoGenomics to buy GE cancer diagnostics biz Clarient for $300M

Oncology genomics player NeoGenomics is slated to buy GE cancer diagnostic unit Clarient Diagnostic Services in a cash and stock deal worth about $300 million. That's an impressive feat given that NeoGenomics' market cap was less than $350 million prior to the deal announcement.

Michigan governor urges Perrigo shareholders to reject Mylan's offer

Some of Perrigo's shareholders have already spoken out against Mylan's hostile pursuit of the company. But now, Michigan Governor Rick Snyder is getting on board.

With Opsumit launch rolling, Actelion doesn't 'need' M&A: CEO

Back in 2013, Actelion launched Opsumit, a new-and-improved pulmonary arterial hypertension drug it hoped would help make up sales for its aging Tracleer. And so far, everything is going according to plan.

Valeant to acquire in-office noninvasive ocular allergy Dx startup Doctor's Allergy

Valeant's Bausch + Lomb business will acquire ophthalmic diagnostic startup Doctor's Allergy Formula for an undisclosed amount. The eye health business will gain an FDA-approved test to diagnose and identify the cause of ocular allergies--with the expectation that the test is becoming the standard of care.